Alnylam Pharmaceuticals develops novel therapeutics based on RNA interference. Marketed products include ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. The company also develops treatments for various diseases, including transthyretin amyloidosis, complement-mediated diseases, and more. Alnylam has collaborations with Regeneron Pharmaceuticals and Roche to develop RNAi therapeutics. It also has license and collaboration agreements with Novartis AG, Vir Biotechnology, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 100.0 |